<DOC>
	<DOCNO>NCT02353039</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety investigational product patient gastritis participation study .</brief_summary>
	<brief_title>Phase II Study Evaluate Efficacy Safety GC6101A Subjects With Gastritis</brief_title>
	<detailed_description>GC6101A botanical drug product make Lonicerae Flos . Two hundred volunteer participate study , receive 2-week treatment GC6101A placebo .</detailed_description>
	<mesh_term>Gastritis</mesh_term>
	<criteria>Age 19 year old , men woman Patients diagnose acute chronic gastritis gastroscopy Patients one erosion find gastroscopy Signed inform consent form Patients impossible receive gastroscopy Patients peptic ulcer gastroesophageal reflux disease Patients gastroesophageal surgery surgery reduce secretion gastric acid ( Except surgery perforate peptic ulcer cecectomy ) Patients esophageal varix Patients malignant neoplasm gastrointestinal tract Patients thrombosis administer antithrombotic drug Patients consumption coagulopathy Patients administer H2 receptor antagonist , muscarinic receptor antagonist , gastrin receptor antagonist , proton pump inhibitor , prostaglandin mucosal protective agent prior study 2 week Patient interrupt steroid , nonsteroid antiinflammatory drug aspirin treatment Allergic hypersensitive ingredient test product Pregnant lactate female Patients abnormal baseline laboratory test result Patients take investigational drug within 30 day prior study . Patients ZollingerEllison syndrome Patients investigator consider ineligible study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>